Beam Therapeutics Inc
Biotechnology
Beam Therapeutics Inc (BEAM) Stock News
The latest BEAM headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
EVA LIVE TARGETS A $3 TRILLION GLOBAL DEFENSE, SATELLITE AND AI INFRASTRUCTURE OPPORTUNITY WITH PROPOSED ACQUISITION OF AIRBEAM WIRELESS TECHNOLOGIES
Eva Live Inc. (NASDAQ: GOAI) announced a Letter of Intent to acquire a controlling 51% interest in Airbeam Wireless Technologies for approximately $16 million, with an option to acquire the remaining 49%. The acquisition provides access to over 260 patents and advanced millimeter-wave semiconductor technology built on more than $150 million in cumulative R&D investment. Eva Live aims to combine Airbeam's wireless technology with its AI platform to develop next-generation communications for autonomous drone swarms, resilient military networks, smart cities, and satellite infrastructure, targeting a $3 trillion global opportunity.
- GlobeNewswire Inc.·
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Beam Therapeutics presented additional clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) at the American Thoracic Society conference. The data from 29 patients showed durable efficacy, improved safety profile, and reduction in neutrophil elastase activity. The company plans to pursue an accelerated FDA approval pathway and expects to initiate a pivotal cohort with approximately 50 additional patients in the second half of 2026.